A. Chan

发表

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

M. Berger, S. Stein, C. Geyer, 2006, The New England journal of medicine.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

M. Casey, S. Stein, C. Geyer, 2008, Breast Cancer Research and Treatment.

Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

H. Wildiers, J. Carmichael, C. Singer, 2010 .

RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer

J. Bergh, C. Hudis, W. Gradishar, 2017, Clinical breast cancer.

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

P. Fasching, P. Neven, F. Esteva, 2020, Breast.

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

L. Chow, A. Wolff, A. Berkenblit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients.

A. Chan, S. Mcgregor, Wenbin Liang, 2014, Breast.

Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required

J. Beith, R. Lakhanpal, R. Stuart-Harris, 2013 .

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

V. Semiglazov, L. Gianni, P. Valagussa, 2016 .

Male Breast Cancer in Australia

A. Chan, Christopher M Reid, H. Chih, 2020, Asia-Pacific journal of clinical oncology.

Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens.

A. Chan, Christopher M Reid, A. Bauwens, 2018, Breast.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D. Miles, L. Dirix, G. Romieu, 2013, British Journal of Cancer.

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A. Morey, A. Chan, D. Ingram, 2012, BMC Cancer.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

R. Snyder, A. Chan, B. Mookerjee, 2013, Investigational New Drugs.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

R. Greil, E. Winer, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

M. Campone, A. Manikhas, L. Dirix, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Antiangiogenic Therapy for Metastatic Breast Cancer

A. Chan, A. Chan, 2012, Drugs.

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.

Sung-Bae Kim, S. Goel, F. André, 2020, The Lancet. Oncology.

Challenges to effective cancer control in China, India, and Russia.

Jun Wang, Shiying Yu, Arlene Chan, 2014, The Lancet. Oncology.

Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).

N. Robert, M. Gnant, H. Iwata, 2015 .

TILs in metastatic breast cancer-no surprises, but more questions.

A. Chan, 2017, The Lancet. Oncology.

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

A. Chan, A. Chan, 2016, Therapeutic advances in medical oncology.

Phase II, open‐label trial of lapatinib and vinorelbine in women with previously treated HER2‐positive metastatic breast cancer

P. Craft, A. Redfern, A. Chan, 2014, Asia-Pacific journal of clinical oncology.

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

H. Sommer, M. Untch, P. Kellokumpu-Lehtinen, 2006, British Journal of Cancer.

The role of capecitabine in first-line treatment for patients with metastatic breast cancer.

K. Gelmon, N. Harbeck, A. Chan, 2006, The oncologist.

Final Results of the Randomized Phase II NorCap‐CA223 Trial Comparing First‐Line All‐Oral Versus Taxane‐Based Chemotherapy for HER2‐Negative Metastatic Breast Cancer

A. Barnadas, A. Chan, Michiel Botha, 2017, Clinical breast cancer.

Capecitabine and vinorelbine in metastatic breast cancer.

A. Chan, M. Verrill, A. Chan, 2009, European journal of cancer.

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

J. Mackey, N. Robert, V. Valero, 2016 .

Pigment epithelium-derived factor regulation of neuronal and stem cell fate.

C. Dass, A. Chan, Emily Brook, 2020, Experimental cell research.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.

A. Schneeweiss, N. Harbeck, D. Miles, 2009 .

Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2- advanced breast cancer (ABC).

G. Hortobagyi, F. Esteva, D. Tripathy, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 positive metastatic breast cancer: What happens after first line failure?

A. Chan, 2016 .

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Mackey, N. Robert, W. Eiermann, 2013, The oncologist.

T. Pintér, T. Fornander, T. Pieńkowski, 2013 .

Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor

A. Chan, John C. Su, A. Yazdabadi, 2021, Asia-Pacific journal of clinical oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Pigment epithelium-derived factor downregulation in oestrogen receptor positive breast cancer bone metastases is associated with menopause

C. Dass, A. Chan, A. Dharmarajan, 2022, Molecular and Cellular Endocrinology.

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

A. Redfern, A. Chan, D. Tsoi, 2021, Asia-Pacific journal of clinical oncology.

Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.

A. Chan, A. Gajdatsy, R. D. de Boer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positive Early Breast Cancer : Results from the BCIRG Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Health-Related Quality of Life With Adjuvant Docetaxel

J. Mackey, N. Robert, W. Eiermann, 2013 .

The role of pigment epithelium-derived factor in protecting against cellular stress

C. Dass, A. Chan, Emily Brook, 2019, Free radical research.

Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study.

D. Miles, H. Samonigg, J. Beith, 2009 .

Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study)

A. Chan, P. Willsher, D. Hastrich, 2017, Supportive Care in Cancer.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Sung-Bae Kim, H. Iwata, Bing-he Xu, 2019, Future oncology.

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sung-Bae Kim, R. Greil, S. Kuemmel, 2021, Clinical Cancer Research.

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.

A. Giuliano, D. Hoon, C. Kuo, 2001, Cancer research.

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2‐positive breast cancer

P. Craft, P. Mainwaring, N. Wilcken, 2009 .

NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer

C. Dass, A. Chan, A. Dharmarajan, 2022, International journal of molecular sciences.

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

C. Dass, A. Chan, Emily Brook, 2020, Cancers.

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

R. Greil, A. Schneeweiss, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

John R. Mackey, Marc Buyse, Arlene Chan, 2009 .

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Sung-Bae Kim, B. Gril, J. Kurebayashi, 2010, Japanese journal of clinical oncology.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

P. Neven, D. Slamon, S. Chia, 2020 .

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

H. Wildiers, J. Carmichael, C. Watkins, 2013, Breast Cancer Research.

Breast cancer bone metastases: pathogenesis and therapeutic targets.

C. Dass, A. Chan, Emily Brook, 2018, The international journal of biochemistry & cell biology.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Sung-Bae Kim, M. Buyse, M. Gnant, 2017, The Lancet. Oncology.

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

H. Rugo, M. Gnant, H. Iwata, 2020, Clinical breast cancer.

A review of the importance of immune responses in luminal B breast cancer

A. Chan, K. Munyard, D. Nelson, 2017, Oncoimmunology.

Adjuvant trastuzumab in HER2-positive breast cancer.

Marc Buyse, Arlene Chan, Marek Pawlicki, 2011, The New England journal of medicine.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

N. Harbeck, D. Miles, L. Dirix, 2008 .

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

P. Neven, A. Bardia, F. Esteva, 2021, British Journal of Cancer.

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

N. Lin, C. Anders, P. Kabos, 2020, Clinical Cancer Research.

Adjuvant Trastuzumab in HER 2-Positive Breast Cancer

M. Buyse, G. Sauter, J. Mackey, 2011 .

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.

A. Chan, A. Chan, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

E. Winer, P. Morris, H. Rugo, 2021, The Lancet. Oncology.

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

A. Schneeweiss, J. Baselga, A. Zubel, 2010 .

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

R. Greil, J. Bergh, K. Kern, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

L. Gianni, P. Valagussa, L. Calvo, 2018, JAMA oncology.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

M. Buyse, L. Fallowfield, D. Cella, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Osteonecrosis of the jaw in an anti-resorptive naïve patient taking trastuzumab and pertuzumab: case report.

A. Chan, N. Vujcich, T. Manzie, 2019, Australian dental journal.

Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial

D. Tripathy, N. Iannotti, C. Barcenas, 2017 .

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.

H. Iwata, D. Finkelstein, C. Barrios, 2019, The Lancet. Oncology.

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.

B. Ramaswamy, K. Blackwell, J. Sparano, 2017 .

Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

D. Tripathy, M. Trudeau, A. Brufsky, 2021 .

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

X. Pivot, J. Lotz, A. Chan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II study of XRP 6258 administered as a 1h i . v . infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

X. Pivot, J. Lotz, A. Chan, 2008 .

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

D. Miles, X. Pivot, A. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.

S. Loibl, J. Crawford, A. Chan, 2012, Critical reviews in oncology/hematology.

Use of non‐anthracycline regimens in early stage breast cancer in Australia

B. Tran, A. Chan, N. Wilcken, 2011, Asia-Pacific journal of clinical oncology.

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

P. Mainwaring, B. Koczwara, P. Kaufman, 2012, Breast Cancer Research and Treatment.

Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

H. Iwata, D. Finkelstein, C. Barrios, 2018 .

Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials

P. Neven, A. Bardia, L. Hart, 2019, Poster Session Abstracts.

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

J. Herranz, J. Albanell, L. Gianni, 2022, Frontiers in Oncology.

Potential therapeutic role for pigment epithelium-derived factor in post-menopausal breast cancer bone metastasis.

C. Dass, A. Chan, A. Dharmarajan, 2023, The Journal of pharmacy and pharmacology.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

M. Espié, V. Ganju, P. Conte, 2013, Anticancer research.

A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western Australia

J. Goldblatt, A. Chan, E. Wylie, 2009, The Medical journal of Australia.

Prognostic role of immune environment in luminal B early breast cancer

A. Chan, D. Nelson, H. Chih, 2023, Cancer medicine.

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

M. Espié, P. Conte, P. Conte, 2009, British Journal of Cancer.

2130 POSTER Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC)

M. Espié, P. Conte, A. Chan, 2007 .

149ONeratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

M. Buyse, M. Gnant, H. Iwata, 2017 .

Lapatinib - overview and current role in metastatic breast cancer.

A. Chan, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Maristela L Onozato, A. Iafrate, M. Onozato, 2017, Cancer discovery.

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

I. Láng, Z. Horváth, A. Chan, 2018, Cancer medicine.

Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2

G. Hortobagyi, M. Campone, L. Hart, 2018 .

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

G. Hortobagyi, F. André, M. Campone, 2016 .

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

Preoperative taxane‐based chemotherapy in a standardized protocol for locally advanced breast cancer

A. Redfern, A. Chan, B. Latham, 2012, Asia-Pacific journal of clinical oncology.

Neratinib after trastuzumab in patients with HER2-positive breast cancer Reply

M. Buyse, A. Chan, B. Yao, 2016 .

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.

M. Buyse, A. Chan, B. Yao, 2016, The Lancet. Oncology.

Psychosocial consequences in offspring of women with breast cancer

A. Chan, Christopher M Reid, P. Willsher, 2019, Psycho-oncology.

Compliance with multidisciplinary team meeting management recommendations

A. Chan, Mandy Taylor, P. Willsher, 2019, Asia-Pacific journal of clinical oncology.

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A. Morey, A. Chan, D. Ingram, 2012, BMC Cancer.

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

G. Ball, I. Ellis, S. Pinder, 2014, Clinical Cancer Research.

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

E. Winer, M. Campone, H. Burris, 2017 .

Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer

Benoît Cadieux, A. Chan, R. Coleman, 2021, Advances in Therapy.

Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer

S. Raman, J. Hecht, E. Chan, 2020 .

Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2019, Journal of Clinical Oncology.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Sung-Bae Kim, M. Buyse, N. Robert, 2019, Breast Cancer Research.

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

H. Iwata, N. Ternès, M. Campone, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.

G. Hortobagyi, L. Hart, C. Arteaga, 2018 .

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

G. Hortobagyi, F. André, M. Campone, 2017 .

Magnetic resonance findings in women at high risk for developing breast cancer: An Australian feasibility study

J. Goldblatt, A. Chan, E. Wylie, 2008, Journal of medical imaging and radiation oncology.